• Journal of Genetic Medicine
• /
• 제7권1호
• /
• pp.16-23
• /
• 2010

많은 내분비 질환이 유전적 요소를 갖고 있다. 단일 유전자 질환에서는 유전적 요인이 주요 원인이나 다인자성 질환에서는 환경과 생활습관 등이 함께 병인으로 작용한다. 유전성 내분비 질환의 분자유전학적 병인에 대한 이해에 대하여 최근 많은 발전이 있어 왔으며 분자유전학적 기술의 응용으로 질환에 대한 이해와 이를 이용한 진단 및 유전 상담에 도움이 되고 있다. 유전학적 검사로 특정 질환의 돌연변이를 증명하는 것은 진단이 모호한 경우에서 정확한 진단과 산전 진단, 보인자 검사에 적용될 수 있다. 그러나 유전자 검사만으로 임신 중절과 관련된 산전 진단에 이용하는 데에는 신중을 기해야 한다.

• Asian-Australasian Journal of Animal Sciences
• /
• 제15권12호
• /
• pp.1822-1830
• /
• 2002

The microsatellites are the short tandem repeats of 1 to 6 bp long monomer sequences that are repeated several times. These short tandem repeats are considered to be generated by the slipped strand mispairing. Based on the unique capability of alternating purine-pyrimidine residues to form Z-DNA, the possible role of the microsatellites in gene regulation has been proposed. The microsatellites are highly polymorphic, follow Mendelian inheritance and are evenly distributed throughout the genomes of eukaryotes. They are easy to isolate and the polymerase chain reaction based typing of the alleles can be readily automated. These properties make them the preferred markers for comparison of the genetic structure of the closely related breeds/populations; very high-resolution genetic mapping and parentage testing etc. The microsatellites have rapidly replaced the restriction fragment length polymorphism (RFLP) and the random amplified polymorphic DNA (RAPD) in most applications in the population genetics studies in most species, including the various farm animals viz. cattle, buffalo, goat, sheep and pigs etc. More and more reports are now available describing the use of microsatellites in pigs ranging from measurement of genetic variation between breeds/populations, developing high resolution genetic maps to identifying and mapping genes of biological and economic importance.

• Journal of Plant Biotechnology
• /
• 제33권4호
• /
• pp.289-295
• /
• 2006

국내에서 유통되고 있는 토마토 품종의 판별 방법에 SSR marker의 이용 가능성에 대한 연구를 수행하여 얻어진 결과를 요약하면 다음과 같다. 토마토 28품종을 18개의 SSR marker를 이용하여 분석하였을 때 대립유전자의 수는 $2{\sim}9$개로 비교적 다양한 분포를 나타내었으며 전체 60개의 대립유전자가 분석되었다. PIC 값은 $0.476 {\sim}0.800$ 범위에 속하였으며 평균값은 0.607로 나타났다. SSR marker를 이용하여 작성된 토마토 28품종의 품종간 유전적 거리는 $0.35{\sim}0.97$의 범위로 나타났고, 유사도 지수 0.36을 기준으로 할 때 28개 품종은 체리형 토마토 그룹과 일반형 토마토 그룹으로 나눌 수 있었으며, 공시 품종 모두 SSR marker의 genotype에 의해 뚜렷이 구분되었다. 이 연구결과는 토마토의 품종식별에 기초 자료로 유용하게 이용될 수 있는 것으로 나타났다.

• Clinical and Experimental Reproductive Medicine
• /
• 제49권3호
• /
• pp.159-167
• /
• 2022

As the resolution and accuracy of diagnostic techniques for preimplantation genetic testing for aneuploidy (PGT-A) are improving, more mosaic embryos are being identified. Several studies have provided evidence that mosaic embryos have reproductive potential for implantation and healthy live birth. Notably, mosaic embryos with less than 50% aneuploidy have yielded a live birth rate similar to euploid embryos. This concept has led to a major shift in current PGT-A practice, but further evidence and theoretically relevant data are required. Proper guidelines for selecting mosaic embryos suitable for transfer will reduce the number of discarded embryos and increase the chances of successful embryo transfer. We present an updated review of clinical outcomes and practice recommendations for the transfer of mosaic embryos using PGT-A.

• 의료법학
• /
• 제18권1호
• /
• pp.237-264
• /
• 2017

인간게놈프로젝트의 시작과 함께 그 사회적 부작용의 하나로 거론되었던 '유전정보 차별'의 문제가 아직 우리나라에서 크게 부각된 적은 없다. 그러나 2016년 6월 30일부터 시행된 "생명윤리 및 안전에 관한 법률"이 의료기관이 아닌 유전자검사기관의 유전자검사를 예외적으로 허용하자, 국내의 한 보험회사가 신규 암보험 가입자를 대상으로 DTC 유전자 검사를 별도의 무료 서비스로 제공하겠다고 하여 유전자 검사와 관련된 사회적 변화를 실감케 한 바 있다. 정밀의료가 의료의 새로운 표준으로 성큼 다가온 현 시점에서 유전정보 차별에 관한 규율은 더 이상 미룰 수 없는 문제가 되었다. 우리나라는 생명윤리법 제46조, 제67조에서 유전정보를 이유로 한 차별의 금지와 그 위반행위에 대한 벌칙을 규정하고 있지만, 이러한 광범위한 원칙 규정만으로는 보험, 고용 등 구체적인 유전정보 활용 영역에서의 문제점들을 충분히 해결할 수 없다. 미국, 캐나다, 영국, 독일은 상이한 방식으로 유전정보 차별의 문제를 다루고 있다. 미국의 "Genetic Information Non-Discrimination Act"의 경우, 건강보험과 관련된 부분은 기존의 법에 유전정보 차별금지에 관한 내용을 추가하는 형식을 취하고 있다. 또 개인과 그 가족의 유전자 검사 결과 외에 '가족력'까지 포함하여 유전정보의 범위를 매우 넓게 규정하고 있다. 캐나다는 2017년 비교적 최근에 법을 제정하였는데, 보험과 고용 외에 '상품이나 서비스의 거래'에까지 적용범위를 확장하고 있다. 영국은 유전자 검사 중 '개인의 예측적 유전자 검사'에 대해서만 다루고 있는데, 보험의 경우 영국정부와 보험협회의 '협약'을 통해 유전정보의 활용을 2019년까지 유예하는 방식으로 규율하고 있고, 고용의 영역은 ICO가 만든 'Employment Practices Code(2011)'가 기준으로 활용되고 있다. 독일은 유전자 검사에 관한 법 "Gesetz ${\ddot{u}}ber$ genetische Untersuchungen bei Menschen"에서 고용과 보험에서의 유전자 검사 및 그 결과 제출 요구의 원칙적 금지를 규정하고 있다. 이와 같이 각 나라마다 규율형식, 적용범위 뿐만 아니라 규율의 실효성에 대한 평가도 매우 상이하다. 이러한 점에 비추어 보았을 때 우리나라의 유전정보 차별에 관한 규제 역시 관련 규정의 검토, 전문가 집단의 참여 및 이해관계자의 협력을 통해 여러 규제안의 장 단점을 충분히 검증한 후 입법의 단계로 나아가는 것이 바람직할 것이다.

• Journal of Information Processing Systems
• /
• 제7권2호
• /
• pp.363-384
• /
• 2011

As the complexity of software is increasing, generating an effective test data has become a necessity. This necessity has increased the demand for techniques that can generate test data effectively. This paper proposes a test data generation technique based on adequacy based testing criteria. Adequacy based testing criteria uses the concept of mutation analysis to check the adequacy of test data. In general, mutation analysis is applied after the test data is generated. But, in this work, we propose a technique that applies mutation analysis at the time of test data generation only, rather than applying it after the test data has been generated. This saves significant amount of time (required to generate adequate test cases) as compared to the latter case as the total time in the latter case is the sum of the time to generate test data and the time to apply mutation analysis to the generated test data. We also use genetic algorithms that explore the complete domain of the program to provide near-global optimum solution. In this paper, we first define and explain the proposed technique. Then we validate the proposed technique using ten real time programs. The proposed technique is compared with path testing technique (that use reliability based testing criteria) for these ten programs. The results show that the adequacy based proposed technique is better than the reliability based path testing technique and there is a significant reduce in number of generated test cases and time taken to generate test cases.

• 한국정보시스템학회지:정보시스템연구
• /
• 제12권2호
• /
• pp.1-20
• /
• 2003

This paper deals with the application of the genetic algorithm to the technical trading rule of the stock market. MACD(Moving Average Convergence & Divergence) and the Stochastic techniques are widely used technical trading rules in the financial markets. But, it is necessary to determine the parameters of these trading rules in order to use the trading rules. We use the genetic algorithm to obtain the appropriate values of the parameters. We use the daily KOSPI data of eight years during January 1995 and October 2002 as the experimental data. We divide the total experimental period into learning period and testing period. The genetic algorithm determines the values of parameters for the trading rules during the teaming period and we test the performance of the algorithm during the testing period with the determined parameters. Also, we compare the return of the genetic algorithm with the returns of buy-hold strategy and risk-free asset. From the experiment, we can see that the genetic algorithm outperforms the other strategies. Thus, we can conclude that genetic algorithm can be used successfully to the technical trading rule.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권5호
• /
• pp.2241-2247
• /
• 2012

Objective: This qualitative study retrospectively examined the experience and psychological impact of contralateral prophylactic mastectomy (CPM) among Southern Chinese females with unilateral breast cancer history who underwent BRCA1/2 genetic testing. Limited knowledge is available on this topic especially among Asians; therefore, the aim of this study was to acquire insight from Chinese females' subjective perspectives. Methods: A total of 12 semi-structured in-depth interviews, with 11 female BRCA1/BRCA 2 mutated gene carriers and 1 non-carrier with a history of one-sided breast cancer and genetic testing performed by the Hong Kong Hereditary Breast Cancer Family Registry, who subsequently underwent CPM, were assessed using thematic analysis and a Stage Conceptual Model. Breast cancer history, procedures conducted, cosmetic satisfaction, pain, body image and sexuality issues, and cancer risk perception were discussed. Retrieval of medical records using a prospective database was also performed. Results: All participants opted for prophylaxis due to their reservations concerning the efficacy of surveillance and worries of recurrent breast cancer risk. Most participants were satisfied with the overall results and their decision. One-fourth expressed different extents of regrets. Psychological relief and decreased breast cancer risk were stated as major benefits. Spouses' reactions and support were crucial for post-surgery sexual satisfaction and long-term adjustment. Conclusions: Our findings indicate that thorough education on cancer risk and realistic expectations of surgery outcomes are crucial for positive adjustment after CPM. Appropriate genetic counseling and pre-and post-surgery psychological counseling were necessary. This study adds valuable contextual insights into the experiences of living with breast cancer fear and the importance of involving spouses when counseling these patients.

• Genomics & Informatics
• /
• 제12권4호
• /
• pp.151-155
• /
• 2014

In November 2013, the US Food and Drug Administration (FDA) sent a warning letter to 23andMe, Inc. and ordered the company to discontinue marketing of the 23andMe Personal Genome Service (PGS) until it receives FDA marketing authorization for the device. The FDA considers the PGS as an unclassified medical device, which requires premarket approval or de novo classification. Opponents of the FDA's action expressed their concerns, saying that the FDA is overcautious and paternalistic, which violates consumers' rights and might stifle the consumer genomics field itself, and insisted that the agency should not restrict direct-to-consumer (DTC) genomic testing without empirical evidence of harm. Proponents support the agency's action as protection of consumers from potentially invalid and almost useless information. This action was also significant, since it reflected the FDA's attitude towards medical application of next-generation sequencing techniques. In this review, we followed up on the FDA-23andMe incident and evaluated the problems and prospects for DTC genetic testing.

• Journal of Genetic Medicine
• /
• 제15권2호
• /
• pp.55-63
• /
• 2018

Clinical and genetic heterogeneity in association with overlapping spectrum is characteristic in pediatric neuromuscular disorders, which makes confirmative diagnosis difficult and time consuming. Considering evolution of molecular genetic diagnosis and resultant upcoming genetically modifiable therapeutic options, rapid and cost-effective genetic testing should be applied in conjunction with existing diagnostic methods of clinical examinations, laboratory tests, electrophysiologic studies and pathologic studies. Earlier correct diagnosis would enable better clinical management for these patients in addition to new genetic drug options and genetic counseling.